The role of inflammation in driving COVID-19 morbidity and mortality has also been studied in clinical trials using anti-inflammatory therapies, including glucocorticoids and IL-6 inhibitors, and reporting their improving effects on mortality and organ complications in severe COVID-19 patients [25,26,27,28]. Here, IL6 is linked to COVID-19.